GLP-1 Drugs Show Anti-Inflammatory Promise for Autoimmune Diseases | Research

The takeaway

Systematic review suggests GLP-1 receptor agonists may reduce inflammation in immune-mediated inflammatory diseases, though evidence remains heterogeneous.

Anti-inflammatory beyond metabolism
GLP-1 RAs showed IMID benefits but heterogeneity prevented meta-analysis

What the researchers found

GLP-1 RAs demonstrated anti-inflammatory effects in patients with immune-mediated inflammatory disorders, though significant heterogeneity prevented meta-analysis.

Why it matters

Millions of people have autoimmune inflammatory diseases with limited treatment options. If GLP-1 drugs can double as anti-inflammatory agents, they could benefit patients with both metabolic and immune conditions.

How the study worked

Systematic review of PubMed, Scopus, and Embase (searched April 2025) for studies reporting GLP-1 RA use in patients with IMIDs.

What this study cannot tell us

Significant heterogeneity prevented meta-analysis. Most evidence comes from observational studies or secondary analyses of metabolic trials.

How to read the evidence

Systematic review without meta-analysis due to heterogeneity — provides overview but not pooled estimates.

When this study was published

Published in 2026; searched through April 2025.

The bigger picture

This supports the broader narrative that GLP-1 drugs have systemic anti-inflammatory effects beyond metabolic control, potentially benefiting a wide range of chronic diseases.

Questions still open

Should GLP-1 drugs be tested in dedicated trials for specific autoimmune diseases?
Which IMIDs are most likely to benefit from GLP-1 RA anti-inflammatory effects?

Common questions

Can GLP-1 drugs treat autoimmune diseases?

Evidence suggests GLP-1 drugs have anti-inflammatory properties that may benefit autoimmune conditions, but they are not yet approved for this purpose. Dedicated clinical trials are needed.

Which autoimmune diseases might benefit from GLP-1 drugs?

Early evidence suggests potential benefits in psoriasis, inflammatory bowel disease, and other immune-mediated inflammatory disorders, though more research is needed for each specific condition.

Read the original research

Impact of GLP-1 analogues on immune-mediated inflammatory diseases: A systematic review.

Autoimmunity reviews, 25(1), 103936

View on PubMed ↗Publisher’s paper ↗

Citation

Birda, Chhagan L; Ibrahim, Fadwa; Chatterjee, Abhirup; Jena, Anuraag; Sharma, Vishal; Sebastian, Shaji. (2026). Impact of GLP-1 analogues on immune-mediated inflammatory diseases: A systematic review.. Autoimmunity reviews, 25(1), 103936. https://doi.org/10.1016/j.autrev.2025.103936